Anumana
Cambridge, US · Founded 2020 · Delaware corporation · 3 known investors
Find your way into Anumana
Sign up to find every way you can get introduced to Anumana
- Your email: who you already know at Anumana, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Anumana team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Anumana is an AI-driven health technology company developing software-as-a-medical-device (SaMD) solutions that apply AI to standard 12-lead ECG data to detect early signs of cardiovascular disease and support clinical decision-making. Its portfolio includes FDA-cleared ECG-AI algorithms, generative imaging applications, and real-time procedural support tools for use across diagnostic and intraprocedural cardiac care.
Founders & leadership
Anumana was founded in 2020 by Murali Aravamudan.

Investors · 3
How we know: NTT Venture Capital's portfolio page · funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$32M disclosed across 1 round · 2022
▶$32MraisedNov 2022 · 72 investors · BiotechnologyRule 506(b)
- Murali AravamudanExecutive Officer, Director
- Harris FishmanExecutive Officer
- Alan ColowickDirector
- Cheranjit RihalDirector
- David GoelDirector
- Kyle BettigoleExecutive Officer
- Offering amount
- $32M
- Amount sold
- $32M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Anumana.
In the news
Frequently asked questions
- What does Anumana do?
- Anumana is an AI-driven health technology company developing software-as-a-medical-device (SaMD) solutions that apply AI to standard 12-lead ECG data to detect early signs of cardiovascular disease and support clinical decision-making. Its portfolio includes FDA-cleared ECG-AI algorithms, generative imaging applications, and real-time procedural support tools for use across diagnostic and intraprocedural cardiac care.
- Who founded Anumana?
- Anumana was founded by Murali Aravamudan in 2020.
- Who are Anumana's investors?
- Anumana's investors include NTT Venture Capital, Matrix, Matrix Capital Management.
- How much funding has Anumana raised?
- Anumana has disclosed $32M raised across 1 round.
- Where is Anumana headquartered?
- Anumana is headquartered in Cambridge, US.




